Where does Jan H.M. Schellens work?

Jan H.M. Schellens is Chief Medical Officer at Adcytherix.

Where did Jan H.M. Schellens go to school?

Jan H.M. Schellens studied at European Certified Pharmacologists Programme (European Certified Pharmacologist (EuCP), Pharmacology); Utrecht University (Board Certified Clinical Pharmacologist, Medicine); Erasmus University Rotterdam (Board certified Pharmacologist, Pharmacology).

Jan H.M. Schellens

Chief Medical Officer at Adcytherix

Utrecht Area

Find your path to Jan

156 people in our graph share verified history with Jan — schools, employers, funds. One of them is your warm intro.

Erik MeijerunlockedJan: together at Utrecht University (1999–2000)

×2Jan: together at Utrecht University

×9Jan: together at Leiden University

About

Jan H.M. Schellens serves as Chief Medical Officer at Adcytherix SA, with specialties including medical oncology, translational and clinical oncology research, clinical pharmacology, and regulatory strategy. Between 2003 and 2019 he provided consulting to pharmaceutical companies including Merck, Eli Lilly, Roche, Novartis, and AstraZeneca, and held administrative roles with the European Medicines Agency, where he chaired the Scientific Advisory Group on Oncology from 2010 to 2016, and the EORTC. He was a board member of the Dutch Medicines Evaluation Board (CBG-MEB) from 1999 to 2016 and cofounded Modra Pharmaceuticals B.V. in 2010.

Chief Medical Officer at Adcytherix

Intro paths

→

In turn, Jan can intro founders to Adcytherix's investors below.

Adcytherix's investors · 8

aMoonRa'anana Andera PartnersParis Angelini VenturesRome BpifranceParis, Ile-De-France · $270K checks Kurma PartnersParis · $162K – $10.8M checks Pontifax Venture CapitalHerzeliya · $6.3M – $128M checks Pureos BioventuresPfäffikon RA CapitalBoston

Co-founders at Adcytherix

Jack ElandsFounder & CEO

Xavier PrevilleCo-founder, VP & Head of Research & Preclinical Development

Experience

Adcytherix SAChief Medical Officercurrent2025 — present
GLGHealthcare Consultantcurrent2024 — presentAmsterdam Area
Modra PharmaceuticalsChief Medical Officer2016 — 2025Amsterdam, North Holland, Netherlands
Skymab BiotherapeuticsChief Medical Officer2024 — 2025
Lixte Biotechnology Holdings, Inc.Chief Medical Officer2024 — 2025
ByondisBoard Member2019 — 2023Nijmegen, The Netherlands
ByondisChief Medical Officer2019 — 2023Nijmegen, Gelderland, Netherlands
DebiopharmSenior Consultant2017 — 2018Lausanne, Vaud, Switzerland
The Netherlands Cancer InstituteHead Department of Pharmacology2016 — 2018Amsterdam, North Holland, Netherlands
The Netherlands Cancer InstituteHead Department of Clinical Pharmacology2006 — 2018Amsterdam, North Holland, Netherlands
The Netherlands Cancer InstituteStaff member Department of Medical Oncology1996 — 2018Amsterdam, North Holland, Netherlands
Utrecht UniversityProfessor of Clinical Pharmacology1999 — 2018Utrecht, Netherlands
Dr Daniel den Hoed Kliniek-ErasmusMCHead of the Laboratory of Experimental Chemotherapy and Pharmacology1991 — 1996Rotterdam, South Holland, Netherlands
Dr Daniel den Hoek Kliniek-ErasmusMCStaff member Department of Medical Oncology1991 — 1996Rotterdam, South Holland, Netherlands

Skills & more

Investigational New Drug Application (IND)C Level ManagementCMO managementMedical OperationsClinical StrategyClinical Study DesignCMOS1Consulting1Medicine1FundraisingC SuiteRare Diseases

+12 more

Translational MedicineBoard of DirectorsStrategic LeadershipPharmaceuticalsCancer ImmunotherapyTrial ManagementMedical AffairsCancer BiologyPharmacologyInterpersonal SkillsLeadershipStrategy

Languages Dutch · English · German · Italian

Authorized by the Dutch Society for Clinical Pharmacology and Biopharmacy to train MD's and pharmacists in Clinical Pharmacology — Nederlandse Vereniging voor Klinische Farmacologie & Biofarmacie (NVKF&B)
Authorized by the NIV (Dutch Society for Internal Medicine) to train internists in Clinical Pharmacology — Nederlandse Internisten Vereniging

From Jan's professional profile.

Frequently asked questions

Who is Jan H.M. Schellens?: Jan H.M. Schellens serves as Chief Medical Officer at Adcytherix SA, with specialties including medical oncology, translational and clinical oncology research, clinical pharmacology, and regulatory strategy. Between 2003 and 2019 he provided consulting to pharmaceutical companies including Merck, Eli Lilly, Roche, Novartis, and AstraZeneca, and held administrative roles with the European Medicines Agency, where he chaired the Scientific Advisory Group on Oncology from 2010 to 2016, and the EORTC. He was a board member of the Dutch Medicines Evaluation Board (CBG-MEB) from 1999 to 2016 and cofounded Modra Pharmaceuticals B.V. in 2010.
Where does Jan H.M. Schellens work?: Jan H.M. Schellens is Chief Medical Officer at Adcytherix.
Where did Jan H.M. Schellens go to school?: Jan H.M. Schellens studied at European Certified Pharmacologists Programme (European Certified Pharmacologist (EuCP), Pharmacology); Utrecht University (Board Certified Clinical Pharmacologist, Medicine); Erasmus University Rotterdam (Board certified Pharmacologist, Pharmacology).

Connect

LinkedIn ↗

Boards & roles

Adcytherix

Education

European Certified Pharmacologists Programme2022European Certified Pharmacologist (EuCP), Pharmacology
Utrecht University1997Board Certified Clinical Pharmacologist, Medicine
Erasmus University Rotterdam1994Board certified Pharmacologist, Pharmacology
Erasmus University Rotterdam1993Board Certified Medical Oncologist, Medicine
Leiden University1991Board certified medical specialist Internal Medicine, Medicine
Leiden University1988Doctor of Philosophy - PhD, Pharmaceutical Sciences
Utrecht University1984BIG registration 69023712201, Medicine
Utrecht University1984Doctor of Medicine - MD, Medicine
Utrecht University1983Master's degree, Medicine
Utrecht University1978Bachelor of Science - BS, Chemistry